One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock.
According to 20 analysts, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)'s revenue estimates for the current quarter are $6.26B meanwhile the company has high revenue estimates of $6.42B in contradiction of low revenue estimates of $6.08B. In the past 5 years, the stock showed growth of -0.84% per annum. Comparatively, growth in the past five years was -0.84 percent (per annum). Teva Pharmaceutical Industries Limited has a 12-month low of $32.11 and a 12-month high of $62.31. Maximum EPS estimate that expected in next quarter is noted at $1.3 and minimum forecasted EPS is calculated at $1.05. Credit Suisse already conservatively assumes 2017 generic competition in its Teva base case so today's news did not lead the firm to change is current estimates. The High Revenue estimate is predicted as 6.42 Billion, while the Low Revenue Estimate prediction stands at 6.08 Billion. During the same quarter in the previous year, the company posted $1.35 EPS.
Price Target plays a critical role when it comes to the Analysis of a Stock.
President Trump says airport chaos is not because of his ban
The president, he wrote , "is right to make sure we are doing everything possible to know exactly who is entering our country". He said Senate Democrats will move quickly to introduce legislation to reverse the order.
Earlier this month, Teva updated its revenue and profit outlook and mentioned that the entry of two competitors in February this year in selling generic versions of Copaxone 40 mg would be liable to reduce its revenue by $1-1.2 billion, while earnings per share would fall by $0.65-0.80. The share price is trading in a range of $34.01 - 34.77. As per the agreement, Natco supplies the drug and Mylan markets it in the USA and both the companies will share the profits. Stock performance in last five sessions is recorded as 4.86% while year to date (YTD) performance is 0.33%. The stock's price moved up its 200-day moving average of $23.60. The Company Touched its 52-Week High on Feb 1, 2016 and 52-Week Low on Jan 23, 2017. About 9.63 million shares traded hands or 7.24% up from the average. The Motley Fool recommends Momenta Pharmaceuticals and Teva Pharmaceutical Industries.
For the next 5 years, Teva Pharmaceutical Industries Limited is expecting Growth of 0.6% per annum, whereas in the past 5 years the growth was -0.84% per annum. Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. 7 given Buy rating to the stock whereas no analyst given UNDERPERFORM rating to stock and 14 analysts given HOLD rating. Analyst's mean target price for MA is $120.37 while analysts mean recommendation is 1.90. During the last six months the stock slipped -34.47%. Teva Pharmaceutical Industries Limited's revenue was up 15.3% compared to the same quarter previous year. After trading began at $34.05 the stock was seen hitting $34.7673 as a peak level and $34.01 as the lowest level. While it's Return on Investment (ROI) value is 5.7%.
The companies mentioned in this article are subjects of research reports issued recently by investment firms.